Li Yunchun, Tan Tianzhi, Mo Tingshu, Lu Wusheng, Deng Houfu, Yang Xiaochuan, Li Xiao
Department of Nuclear Medicine, West China Hospital, Sichuan University, Chengdu 610041, China.
Sheng Wu Yi Xue Gong Cheng Xue Za Zhi. 2007 Aug;24(4):857-61.
To study pharmacokinetics of injection of iodine-131 labelling MEI-TUO-XI monoclonal antibody (hepatoma monoclonal antibody HAb18 F(ab')2) in vivo. 24 cases of primary hepatocelluar carcinoma (PHC) were equally divided into the low dose group, middle dose group and high dose group. After the relevant injection was administrated into the hepatic artery of each case, intravenous blood and urine samples were separately collected at different time for determination of the radioactive count ratio (min(-1)). The proportion of 131I-HAb18 F(ab')2 in serum of each blood sample was determined, and the radioactive count ratio (min(-1)) of druggery for each blood sample was revised according to the proportion. The pharmacokinetic parameters were calculated using DAS ver 1.0 (Drug And Statistics for Windows) program. The component of urine radiomaterial was determined and the percentages of urine radioactivity in administration dosage were calculated. The catabolism of the injection with time accorded with dynamics two-compartment model. The catabolism product was mainly free-131I and was excreted via kidney; the urine radioactivity was 47.70%-51.16% of administration dosage during 120 h after administration of drug. Therefore, the pharmacokinetics of the injection can satisfy the clinical demands. The drug dose recommended for clinical use was 27.75 MBq of the injection for each kg of human body.
研究碘-131标记美妥昔单克隆抗体（肝癌单克隆抗体HAb18 F(ab')2）注射液在体内的药代动力学。将24例原发性肝细胞癌（PHC）患者平均分为低剂量组、中剂量组和高剂量组。对每例患者经肝动脉进行相关注射后，于不同时间分别采集静脉血和尿液样本，测定放射性计数率（min⁻¹）。测定各血样血清中131I-HAb18 F(ab')2的比例，并根据该比例校正各血样药物的放射性计数率（min⁻¹）。采用DAS ver 1.0（Windows版药物与统计学）程序计算药代动力学参数。测定尿放射性物质的成分，并计算尿放射性占给药剂量的百分比。该注射液的代谢随时间符合二室动力学模型。代谢产物主要为游离131I，经肾脏排泄；给药后120 h内尿放射性为给药剂量的47.70% - 51.16%。因此，该注射液的药代动力学可满足临床需求。临床推荐用药剂量为每千克人体27.75 MBq该注射液。
